[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607506":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":62,"collaborators":66,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":25,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":25,"maxAge":25,"enrollmentInfo":76,"targetDuration":25,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Texas Tech University Health Sciences Center","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Attention deficit hyperactivity disorder (ADHD)","EXPERIMENTAL","A group of 12 adult males with Attention Deficit Hyperactivity Disorder (ADHD) will be enrolled. Each participant will receive both study conditions in a randomized, single-blinded, repeated-measures crossover design:\n\nActive Condition: One capsule containing 200 mg L-theanine + 200 mg paraxanthine.\n\nPlacebo Condition: One capsule containing 400 mg of corn starch. The order of administration will be randomized, with each participant completing both conditions on separate visits (visits 2 and 3).",[13,14],"Dietary Supplement: L-theanine and paraxanthine","Dietary Supplement: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Autism spectrum disorder (ASD)","A group of 12 adult males with autism spectrum disorder (ASD) will be enrolled. Each participant will receive both study conditions in a randomized, single-blinded, repeated-measures crossover design:\n\nActive Condition: One capsule containing 200 mg L-theanine + 200 mg paraxanthine.\n\nPlacebo Condition: One capsule containing 400 mg of corn starch. The order of administration will be randomized, with each participant completing both conditions on separate visits (visits 2 and 3).",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","L-theanine and paraxanthine","200 mg L-theanine + 200 mg paraxanthine capsule",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","400 mg corn starch capsule",[9,16],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Chathurika S Dhanasekara, MD, PhD","CONTACT","806-743-2378","samudani.dhanasekara@ttuhsc.edu",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},"Chanaka N Kahathuduwa, MD, PhD","806-412-9974","chanaka.kahathuduwa@ttuhsc.edu",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Texas Tech University","RECRUITING","Lubbock","Texas","79430","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-101.85517,33.57786,{"lat":53,"lon":52},[56,60],{"name":57,"role":33,"phone":58,"phoneExt":25,"email":59},"Ann Mastergeorge, PhD","806-834-7162","ann.mastergeorge@ttu.edu",{"name":61,"role":33,"phone":34,"phoneExt":25,"email":35},"Chathurika S Dhanasekara, MBBS, PhD",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Samudani Dhanasekara","Assistant Professor",[67],{"name":42,"class":6},"100607506","l-theanine-and-paraxanthine-for-cognitive-improvement-in-adults-with-adhd-and-asd-100607506",false,"NCT07189442","L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD","Combining L-theanine and Paraxanthine for Transient Improvement of Cognitive Deficits Among Patients With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Series of Translational Pilot Neuroimaging Studies","Inclusion Criteria:\n\nAdults (18+ years) diagnosed by a physician (per self-report) with ADHD or ASD\n\n\\* Participants with a dual diagnosis and ASD and ADHD will be recruited but will only be included in the ASD group - their concurrent ADHD diagnosis will be included as an additional variable in exploratory analyses\n\nExclusion Criteria:\n\n1. Subjects with gross visual or auditory impairments that might limit their ability to perform neuropsychological tasks\n2. Inability to read and follow written instructions\n3. Physical, neurological, intellectual, or psychiatric impairments (except ADHD or ASD) that could affect cognitive and motor functions\n4. Subjects on medications including antidepressants and antipsychotics that may affect performance in the tasks\n5. Subjects on medications that are likely to interact with the administered substances, including regular intake of medication that could alter visual, auditory, cognitive, or motor functions (except stimulants)\n6. History of head injury resulting in loss of consciousness\u002Fhistory of brain surgery\n7. Subjects who have developed adverse effects when caffeine\u002Fparaxanthine \u002FL-theanine\u002Fcorn starch (will be in placebo) containing products were consumed\n8. Subjects who are unwilling or unable to refrain from intake of L-theanine\u002F caffeine\u002F paraxanthine containing food or beverages within the 24 hours prior to each study visit\n9. Intake of drugs containing caffeine, other phosphodiesterase inhibitors, or adenosine receptor blockers within the past 3 months\n10. Intake of medications known to have pharmacological interactions with paraxanthine within the past 3 months\n11. Current\u002Fpast diagnosis of tics or other forms of dyskinesia\n12. History of headache, drowsiness, anxiety, insomnia, or nausea following intake of caffeine or caffeine-containing beverages\n13. Current\u002Fpast history of smoking and\u002For alcohol or drug abuse\n14. Subjects with absolute contraindications to undergo MRI after being screened by the TTNI safety screening sheet (Appendix)\n15. Unwillingness or inability to entirely refrain from the use of electronic devices during study visits\n16. Unwillingness or inability to follow written, on-screen, and verbal instructions given by the study team.","MALE",{"count":77,"type":78},24,"ESTIMATED","INTERVENTIONAL",[81],"NA","This pilot study will test whether combining L-theanine and paraxanthine improves sustained attention, inhibitory control, and overall cognition in adults with ADHD and ASD. Two parallel randomized, single-blinded, repeated-measures crossover trials will be conducted. Participants will complete neuropsychological testing, fMRI scanning, and self-report measures following administration of the L-theanine-paraxanthine combination compared to placebo.",[84,85],"Attention Deficit Hyperactivity Disorder (ADHD)","Autism Spectrum Disorder (ASD)",[87,88,89,90,91],"ADHD","Attention Deficit Hyperactivity Disorder","ASD","Autism spectrum disorder","Autism","2026-02-04",{"date":94,"type":95},"2026-02-05","ACTUAL",{"date":97,"type":95},"2025-10-01",{"date":99,"type":78},"2026-06-01",{"name":5,"class":6},1]